Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Ray-Coquard, I.; Léary, Alexandra; Pignata, Sandro; Cropet, Claire; González-Martı́n, Antonio; Marth, Christian; Nagao, Shoji; Vergote, Ignace; Colombo, Nicoletta; Mäenpää, Johanna; Selle, Frédèric; Sehouli, Jalid; Lorusso, Domenica; María Guerra Alia, Eva; Bogner, Gerhard; Yoshida, Hiroyuki; Lefeuvre-Plesse, C.; Buderath, Paul; Maria Mosconi, Anna; Lortholary, A.; Burges, Alexander; Medioni, J.; Balat, Ayşe; Rodrigues, Manuel; Park‐Simon, Tjoung‐Won; Dubot, Coraline; Denschlag, Dominik; You, Benoît; Pujade-Lauraine, Éric; Harter, Philipp

doi:10.1016/j.annonc.2023.05.005

Public

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Published in Annals of Oncology • May 19, 2023

Authors:

I. Ray-Coquard

Alexandra Léary

Sandro Pignata

Abstract

BACKGROUND: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irr...

Subject

Medicine

Olaparib

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!